Investigation of MicroRNA-21 Expression Levels in Serum and Stool as a Potential Non-Invasive Biomarker for Diagnosis of Colorectal Cancer.
Investigation of MicroRNA-21 Expression Levels in Serum and Stool as a Potential Non-Invasive Biomarker for Diagnosis of Colorectal Cancer.
复制标题
研究血清和粪便中的microRNA-21表达水平是诊断结直肠癌的潜在非侵入性生物标志物。
DOI：
10.18869/acadpub.ibj.21.2.106
复制
发表时间：
2017-03
影响因子：
--
通讯作者：
Saidijam M
中科院分区：
文献类型：
--
作者：
Bastaminejad S;Taherikalani M;Ghanbari R;Akbari A;Shabab N;Saidijam M
大多数癌症研究的重点是探索用于癌症检测的非侵入性生物标志物。在本研究中，我们试图调查 40 名结直肠癌 (CRC) 患者和 40 名健康对照者的血清和粪便样本中 microRNA-21 (miR-21) 的表达水平，作为潜在的诊断标记物。应用实时定量RT-PCR测定血清和粪便中miR-21的相对表达水平。同时，通过受试者工作特征（ROC）曲线分析评估该标志物的敏感性和特异性。与对照组相比，CRC患者血清和粪便中的miR-21表达水平分别上调12.1倍（P<0.05，95% CI：5.774-34.045）和10.0倍（P<0.05，95% CI：0.351-16.260）。 miR-21 的敏感性和特异性分别为 86.05% 和 72.97%（ROC 曲线下面积 [AUC] 为 0.783）。 CRC患者粪便miR-21水平远高于健康对照，敏感性为86.05%，特异性为81.08%（AUC：0.829）。粪便中miR-21的表达水平能够显着区分CRC肿瘤、淋巴结、转移III-IV期和I-II期，敏感性和特异性分别为88.1%和81.6%（AUC：0.872）。本研究结果表明，血清和粪便中的miR-21表达水平可被视为诊断CRC患者的潜在诊断生物标志物。然而，还需要更多的研究来证实 miR-21 作为 CRC 有价值的非侵入性诊断工具的有效性。
Most cancer studies focus on exploring non-invasive biomarkers for cancer detection. In the present study, we sought to investigate the expression level of microRNA-21 (miR-21), as a potential diagnostic marker, in serum and stool samples from 40 patients with colorectal cancer (CRC) and 40 healthy controls. Quantitative real-time RT-PCR was applied to determine the relative expression level of miR-21 in serum and stool. At the same time, the sensitivity and specificity of this marker was evaluated by receiver operating characteristic (ROC) curve analysis. miR-21 expression levels of serum and stool were up-regulated 12.1 (P<0.05, 95% CI: 5.774-34.045) and 10.0 (P<0.05, 95% CI: 0.351-16.260) times in CRC patients, respectively, when compared to the control group. The sensitivity and specificity of miR-21 was found to be 86.05% and 72.97%, respectively (an area under the ROC curve [AUC] of 0.783). The stool miR-21 level in CRC patients was much higher than that in the healthy controls, showing a sensitivity of 86.05% and a specificity of 81.08% (AUC: 0.829). The expression level of miR-21 in stool was able to significantly distinguish CRC tumor, node, metastasis stages III-IV from stages I-II, with a sensitivity and specificity of 88.1% and 81.6%, respectively (AUC: 0.872). The results of this study indicated that miR-21 expression levels in serum and stool can be considered as a potential diagnostic biomarker for the diagnosis of CRC patients. However, more studies are required to confirm the validity of miR-21 as a valuable non-invasive diagnostic tool for CRC.